OLD Mission Capital LLC Acquires Shares of 21,347 Hologic, Inc. (NASDAQ:HOLX)

OLD Mission Capital LLC acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,347 shares of the medical equipment provider's stock, valued at approximately $1,539,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of HOLX. General Partner Inc. bought a new position in shares of Hologic during the 4th quarter worth approximately $26,000. Venturi Wealth Management LLC boosted its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the last quarter. Finally, Smithfield Trust Co lifted its position in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Evercore ISI lowered their price target on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research report on Thursday, February 6th. Raymond James reiterated an "outperform" rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $84.62.

Remove Ads

Hologic Stock Performance

HOLX traded up $0.25 during trading on Monday, hitting $61.11. The stock had a trading volume of 1,611,314 shares, compared to its average volume of 1,841,892. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a 50 day moving average price of $64.30 and a 200-day moving average price of $72.52. Hologic, Inc. has a one year low of $59.06 and a one year high of $84.67. The firm has a market cap of $13.71 billion, a price-to-earnings ratio of 19.21, a P/E/G ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.